Hubei Yuanda

Grandpharma, formerly known as Hubei Yuanda Pharmaceutical, is a diversified global pharmaceutical company headquartered in Wuhan, China. The company focuses on four core pillars: innovative medicines and health management, specialized pharmaceutical preparations, medical devices, and high-quality API manufacturing. Grandpharma has established a significant presence in the fields of precision interventional oncology, nuclear medicine, and ophthalmology through strategic acquisitions and internal R&D. Notably, the company is a leader in the radiopharmaceutical space, possessing a comprehensive pipeline of radionuclide drug conjugates (RDCs) for various cancers. Their commercial portfolio includes a wide range of products spanning cerebro-cardiovascular emergency medicine, respiratory treatments, and ENT care.